2-oxo-4-phenyl-1,2-dihydropyridine-3-carboxylic acid | 133609-29-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 2-oxo-4-phenyl-1,2-dihydropyridine-3-carboxylic acid
• 英文别名: 2-Hydroxy-4-phenylnicotinic acid；2-oxo-4-phenyl-1H-pyridine-3-carboxylic acid
• CAS: 133609-29-7
• 化学式: C₁₂H₉NO₃
• 分子量: 215.208
• InChiKey: IIZBOPAPJFLJBA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  66.4
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-oxo-4-phenyl-1,2-dihydropyridine-3-carboxylic acid 以78%的产率得到
  参考文献：
  名称：

  PRAGER, ROLF H.;TSOPELAS, CHRIS;HEISLER, TERESA, AUSTRAL. J. CHEM., 44,(1991) N, C. 277-285

  摘要：

  DOI：
• 作为产物：
  描述：

  2-oxo-4-phenyl-1,2-dihydropyridine-3-carbonitrile 在 sodium hydroxide 作用下， 生成 2-oxo-4-phenyl-1,2-dihydropyridine-3-carboxylic acid
  参考文献：
  名称：

  Nonpeptidic Inhibitors of Human Leukocyte Elastase. 2. Design, Synthesis, and in vitro Activity of a Series of 3-Amino-6-aryl-2-oxopyridyl Trifluoromethyl Ketones

  摘要：

  A series of potent nonpeptidic inhibitors of the enzyme human leukocyte elastase (HLE) is reported. These inhibitors contain a 3-amino-2-pyridone ring as a central template in which the pyridone carbonyl and 3-position NH group are thought to form important hydrogen bonding interactions with the Val-216 residue of HLE. Substitution of the 6-position of the pyridone ring by various alkyl and aryl groups was found to afford increases in the in vitro potency of these inhibitors. A 6-position phenyl group, compound 10f, was found to result in a large increase in binding affinity, which was not obtained when the phenyl group was placed in either the 4- or 5-position of the molecule. Compound 10f was found to have good selectivity for HLE over other proteolytic enzymes, with the exception of bovine pancreatic chymotrypsin (BPC). Substitution of the 6-phenyl group in these molecules was found to decrease binding affinity for BPC without adversely affecting affinity for HLE.

  DOI：

  10.1021/jm00046a015

文献信息

• [EN] THIENOPYRIDINE DERIVATIVES AND PHARMACEUTICAL COMPOSITION COMPRISING SAME<br/>[FR] DÉRIVÉS DE THIÉNOPYRIDINE ET COMPOSITION PHARMACEUTIQUE LE COMPRENANT
  申请人：WELLMARKER BIO CO LTD

  公开号：WO2019182274A1

  公开（公告）日：2019-09-26

  A thienopyridine derivative compound represented by Formula 1 or pharmaceutically acceptable salts thereof have an excellent inhibitory effect on protein kinase activity, and accordingly, pharmaceutical compositions comprising same can be usefully used for the prevention or treatment of a disease associated with the activity of a protein kinase.

  由化学式1表示的噻吩吡啶衍生物化合物或其药用盐在蛋白激酶活性上具有出色的抑制作用，因此，包含该化合物的药物组合物可用于预防或治疗与蛋白激酶活性相关的疾病。
• Prager, Rolf H.; Tsopelas, Chris; Heisler, Teresa, Australian Journal of Chemistry, 1991, vol. 44, # 2, p. 277 - 285
  作者：Prager, Rolf H.、Tsopelas, Chris、Heisler, Teresa

  DOI：——

  日期：——
• PRAGER, ROLF H.;TSOPELAS, CHRIS;HEISLER, TERESA, AUSTRAL. J. CHEM., 44,(1991) N, C. 277-285
  作者：PRAGER, ROLF H.、TSOPELAS, CHRIS、HEISLER, TERESA

  DOI：——

  日期：——
• MODULATORS OF C3A RECEPTOR AND METHODS OF USE THEREOF
  申请人：ENCYSIVE PHARMACEUTICALS, INC.

  公开号：EP2125739A1

  公开（公告）日：2009-12-02
• PYRROLOTRIAZINE COMPOUNDS AS TAM INHIBITORS
  申请人：Incyte Corporation

  公开号：EP3436461A1

  公开（公告）日：2019-02-06